First-Line Treatment of Primary Biliary Cholangitis
Primary biliary cholangitis (PBC) is a progressive liver condition that requires lifelong pharmacotherapy from the time of diagnosis. Initiating the appropriate first-line agent promptly — and monitoring for adequate biochemical response — is central to preventing disease progression and improving long-term outcomes.
Treatment Approach
The first-line approach involves a specific oral agent taken daily, with body-weight–based dosing, continued indefinitely. Full dosing parameters, administration guidance, and the complete monitoring algorithm are available in the structured protocol below.
Clinical Goals
The key measure of success is biochemical response after one year of therapy — with early-stage patients who achieve defined targets for liver enzyme and bilirubin levels showing transplant-free survival comparable to a healthy population.
References
DOI: 10.1002/hep.32117
- EASL recommends oral UDCA at 13–15 mg/kg/day as the first-line pharmacotherapy for all patients with PBC.
- UDCA is usually continued for life (I, 1).
- Data suggest that the optimum dose is 13–15 mg/kg per day, which can be given as a single oral daily dose or divided doses if tolerability is an issue; anecdotally some patients tolerate liquid preparations better.
- EASL recommends recognition that patients at greatest risk of complications from PBC are those with inadequate biochemical response to therapy, and cirrhosis (II-2, 1).
- EASL recommends recognising that the transplant-free survival for early-stage patients with ALP <1.5 ULN and a normal bilirubin after one year of therapy with UDCA, is not significantly different to a control healthy population (II-2, 1).
View source ↗